Marco Meglio

Marcio Souza, president and chief executive officer at Praxis Precision Medicines provided follow-up thoughts on recently announced positive findings assessing ulixacaltamide in patients with essential tremor.

In this small-scale Turkish-based substudy, stopping eciluzumab appeared to be associated with a “rebound” effect with a high risk of relapse in patients with NMOSD.

Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.

Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge.

One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.

Treatment with Nerivio did not differ from controls in outcomes of newborn weight, miscarriage rate, preterm birth rate, birth defect rate, stillbirths, and rate of newborns meeting developmental milestones 3 months postnatal.

A composite analysis of motor skills, muscle strength, cognitive ability, daily living skills, and biomarker data showed statistically significant benefits with AMO-02.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Beck, PhD. [LISTEN TIME: 15 minutes]

Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.

Half of the treated individuals saw a reduction of more than 50% in the number and duration of epileptic spasms following treatment with CER-0001, a ketogenic therapy.

The agency requested modifications to the REMS program, seeking validation of patients’ meningococcal vaccination status and prophylactic administration of antibodies prior to giving ravulizumab treatment.

The director of the ALS Clinic at Allegheny Health Network provided perspective on the advancements in the treatment and management of adult-onset spinal muscular atrophy.

An expert panel discusses diagnosis and treatment of patients with Parkinson disease, exploring the challenges in managing dyskinesia, finding a balance between OFF episodes and ON time, and current and emerging treatment options.

More than a 40% improvement in ON time without troublesome dyskinesia occurred as patients had their treatment titrated.

A group of esteemed panelists discussed the important values neurology department directors and educators should prioritize when teaching students of the future. [WATCH TIME: 6 minutes]

A trio of former and current neurology department directors discussed ways in which residency and fellowship programs may change as technology and therapeutic capabilities continue to expand. [WATCH TIME: 8 minutes]

When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.

Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.

A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

Swallowing difficulties, a major concern for patients with Parkinson disease, occurred rarely in the study, and were spontaneously resolved over time.

The distinguished investigator at the National Institutes of Health provided insight on the topic of globalizing Parkinson disease genetics, and how it may lead to potential disease-modifying therapies.

The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.

Patients treated with the probiotic saw benefits in non-motor symptoms such as sleep, fatigue, and gastrointestinal outcomes.

Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.

After a year of treatment, patients showed significant improvements in ON time without troublesome dyskinesia, with more apparent effects observed in the high-dose group.

Significant thinning of GCIPL and INL appeared earlier in individuals with Parkinson disease, being discernible several years prior to clinical presentation.

With limited options available in perimenstrual catamenial epilepsy, a phase 4 study seeks to understand whether an FDA-approved agent for focal onset seizures can effectively treat women with difficult-to-manage disease.

Time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted and adjusted analysis.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicole Fowler. [LISTEN TIME: 23 minutes]